Quick Answer
Vicapsys Life Sciences, Inc. reported Net Income Loss of -$1.18 million for the year ending 2023.
- Vicapsys Life Sciences, Inc. showed a decrease of -20.0% in Net Income Loss from 2022 to 2023.
- This data is from Vicapsys Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on October 21, 2024.
- XBRL data for this metric is available from 2019 to 2023 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$442.7 thousand | Q2 2019: -$248.1 thousand | Q3 2019: -$469.3 thousand | Q1 2020: -$364.5 thousand | Q2 2020: -$231.6 thousand | Q3 2020: -$89.2 thousand | Q1 2021: $50.2 thousand | Q2 2021: -$72.1 thousand | Q3 2021: -$111.2 thousand | Q1 2022: -$167.0 thousand | Q2 2022: -$180.1 thousand | Q3 2022: -$145.1 thousand | Q1 2023: -$211.3 thousand | Q2 2023: -$135.7 thousand | Q3 2023: -$240.3 thousand | Q1 2024: -$327.1 thousand | Q2 2024: -$190.1 thousand | Q3 2024: -$235.5 thousand.
- Over the full 5 years of available data (2019 to 2023), Vicapsys Life Sciences, Inc.'s Net Income Loss has grown by 16.1%.
- Historical annual values: Fiscal year 2023: -$1.18 million | Fiscal year 2022: -$984.8 thousand | Fiscal year 2021: -$236.9 thousand | Fiscal year 2020: -$765.8 thousand | Fiscal year 2019: -$1.41 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: